Mass Tort brief
Teva Settles Generic Disputes While Meta Deflects Addiction Claims
Israel’s pharmaceutical giant clears legacy contamination and antitrust liabilities as Meta secures a crucial victory in youth-mental-health litigation.
Mass Tort
Meta successfully stared down its first major youth-addiction trial — establishing a high bar of proof that could deflate parallel product-liability lawsuits worldwide.
BackgroundThis high-stakes litigation seeks to hold tech giants liable for software design features that allegedly trigger youth mental health crises. The legal battle is closely watched in Israel, where families of October 7 victims are pursuing their own NIS 4B suit against Meta.
- The plaintiff dropped all claims without receiving any financial settlement from Meta, following prior out-of-court settlements with rival platforms YouTube, TikTok, and Snap.
- Meta declared that the sudden dismissal proves that legal arguments linking youth behavioral addiction directly to software design algorithms do not hold up under trial scrutiny.
- The outcome will likely weaken the settlement leverage of plaintiffs in 2,500 pending cases that accuse major social media networks of causing intentional psychological harm.
Mass Tort
Teva is resolving its legacy drug-contamination liabilities in North America — paying millions to clear a lingering chemical safety dispute from its balance sheet.
BackgroundMetformin is a widely prescribed medication used to manage blood sugar in patients with type 2 diabetes. Teva, headquartered in Petah Tikva and listed on the Tel Aviv Stock Exchange (TASE), has spent years fighting consumer class actions stemming from a global drug contamination scandal.
- Teva will contribute $3M to the settlement fund to compensate consumers who purchased the contaminated lots, aiming to clear the liability before additional trials begin.
- The litigation focused on the presence of N-nitrosodimethylamine, a probable human carcinogen that laboratory testing revealed exceeded federal safety limits in certain distributed batches.
- The final deadline for consumers to file reimbursement claims under the class-action settlement has been extended to August 5, 2026, to allow more affected patients to participate.
Mass Tort
Teva is paying millions to resolve antitrust claims on its respiratory line — removing a major legal barrier to generic inhaler competition in its largest market.
BackgroundDrugmakers practice what regulators call product-hopping by switching patients to reformatted drug versions right before patents expire to block cheap generics. Teva, Israel's largest drug company and a cornerstone of the Tel Aviv Stock Exchange (TASE), frequently faces these antitrust challenges in its dominant US export market.
- Plaintiffs claimed Teva improperly listed multiple patents in the FDA's regulatory book to extend its monopoly, allowing the company to charge inflated prices for the respiratory treatments.
- Teva agreed to pay $35M and requested the removal of several disputed patents, opening the door for rival manufacturers to eventually introduce cheaper generic versions.
- Affected consumers and healthcare insurers have until July 31, 2026, to file reimbursement claims, wrapping up a costly legal chapter for Teva's US respiratory division.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.